AstraZeneca's (AZN) Buy Rating Reaffirmed at Shore Capital
AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities researchers at Shore Capital in a report released on Friday, August 9th, Digital Look reports.
Other equities research analysts also recently issued research reports about the stock. UBS Group restated a “sell” rating and issued a GBX 5,400 ($70.56) target price on shares of AstraZeneca in a research note on Thursday, July 25th. Goldman Sachs Group boosted their target price on shares of AstraZeneca from GBX 5,000 ($65.33) to GBX 5,500 ($71.87) and gave the company a “sell” rating in a research note on Monday, August 5th. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a research note on Wednesday, August 7th. Credit Suisse Group set a GBX 7,300 ($95.39) target price on shares of AstraZeneca and ...